The Stapled Peptide PM2 Stabilizes p53 Levels and Radiosensitizes Wild-Type p53 Cancer Cells

Area of Science:

• Oncology
• Molecular Biology
• Radiotherapy

Background:

• The tumor suppressor p53 is crucial for cellular stress and DNA damage response.
• Targeting MDM2, a negative regulator of p53, can amplify wild-type p53 expression.
• Combining MDM2 inhibition with external beam radiotherapy (EBRT) may enhance therapeutic outcomes.

Purpose of the Study:

• To assess the efficacy of the novel stapled peptide PM2, which inhibits MDM2.
• To evaluate PM2 as a potential radiosensitizer for combination therapy with EBRT.
• To investigate the underlying mechanisms of PM2 and PM2-EBRT combination in cancer cells.

Main Methods:

• Cell viability assays were performed on cancer cell lines treated with PM2.
• Western Blot and flow cytometry analyzed p53 pathway activation, apoptosis markers (cleaved caspase-3, Noxa), and p53/MDM2 interactions.
• In vitro 3D tumor spheroid models were used to evaluate combination therapy efficacy.

Main Results:

• PM2 treatment reduced cell viability in wild-type p53, HPV-negative cancer cells.
• Combination therapy with PM2 and EBRT demonstrated superior antitumorigenic effects.
• Upregulation of p53, increased apoptosis, and complete spheroid disintegration were observed.

Conclusions:

• PM2 exhibits antitumorigenic effects and potentiates EBRT in wt p53 HPV-negative cancers.
• The combination of PM2 and EBRT shows significant potential for increasing therapeutic efficacy.
• This strategy may lead to a new class of wt p53-specific tumor-targeting compounds with reduced radiotherapy side effects.